Latest Crohn’s and Colitis News and Research
Related Articles Editorial: aminosalicylates in Crohn’s disease-prevalence, risks, costs and time to re-assess? Aliment Pharmacol Ther. 2018 Aug;48(4):487-488 Authors: Mansfield J, MacDougall L PMID: 30588694 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30588694?dopt=Abstract
Read MoreRelated Articles Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. Aliment Pharmacol Ther. 2018 Dec 19;: Authors: Ma C, Guizzetti L, Cipriano LE, Parker CE, Nguyen TM, Gregor JC, Chande N, Feagan BG, Jairath V Abstract BACKGROUND: Aminosalicylates are the most frequently prescribed treatment for ulcerative colitis (UC). In the absence of empirical evidence, clinicians are uncertain whether to continue aminosalicylates in patients with UC after escalating therapy. AIMS: To quantify concomitant aminosalicylate use in…
Read MoreRelated Articles Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis. Dig Dis Sci. 2018 Nov 26;: Authors: Bajpai M, Seril DN, Van Gurp J, Geng X, Alvarez J, Minacapelli CD, Gorin S, Das KK, Poplin E, Cheng J, Amenta PS, Das KM Abstract BACKGROUND: The role of 5-aminosalicylic acid (5-ASA or mesalamine) in the prevention of colorectal cancer in ulcerative colitis (UC) patients was reported, but the effect on molecular targets in UC colon mucosa is unknown. AIM: This observational study…
Read MoreRelated Articles Concomitant Use of Aminosalicylates Is Not Associated with Improved Outcomes in Patients with Ulcerative Colitis Escalated to Vedolizumab. Clin Gastroenterol Hepatol. 2018 Dec 07;: Authors: Ma C, Kotze PG, Almutairdi A, Jairath V, Panaccione R PMID: 30528845 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30528845?dopt=Abstract
Read MoreRelated Articles Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. Gut. 2018 Nov 12;: Authors: Ungaro RC, Limketkai BN, Jensen CB, Allin KH, Agrawal M, Ullman T, Colombel JF, Jess T Abstract OBJECTIVE: The benefit of continuing 5-aminosalicylate (5-ASA) in patients with ulcerative colitis (UC) who initiate anti-tumour necrosis factor-alpha (anti-TNF) biologics is unknown. We aimed to compare clinical outcomes in patients with UC already on 5-ASA who started anti-TNF and then either…
Read MoreEditorial: aminosalicylates in Crohn’s disease-prevalence, risks, costs and time to reassess? Authors’ reply. Aliment Pharmacol Ther. 2018 Aug;48(4):489 Authors: Jairath V, Ma C, Feagan B PMID: 30284736 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30284736?dopt=Abstract
Read MoremiR-206 as a Biomarker for Response to Mesalamine Treatment in Ulcerative Colitis. Inflamm Bowel Dis. 2018 Sep 11;: Authors: Minacapelli CD, Bajpai M, Geng X, Van Gurp J, Poplin E, Amenta PS, Brant SR, Das KM Abstract Background: MicroRNAs (miRNAs) are important post-translational regulators. Elevated levels of miR-206 in ulcerative colitis (UC) were associated with suppression of anti-inflammatory A3 adenosine receptor (A3AR) expression. However, the relationship of miR-206 to histologic remission in UC patients remains unknown. This study correlates expression levels of miR-206 with histologic remission in patients treated via…
Read MoreRelated Articles Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn’s Disease: A Bayesian Network Meta-analysis: Republished. Inflamm Bowel Dis. 2017 May 01;23(5):E26-E37 Authors: Coward S, Kuenzig ME, Hazlewood G, Clement F, McBrien K, Holmes R, Panaccione R, Ghosh S, Seow CH, Rezaie A, Kaplan GG Abstract Background: Induction treatment of mild-to-moderate Crohn’s disease is controversial. Purpose: To compare the induction of remission between different doses of mesalamine, sulfasalazine, corticosteroids, and budesonide for active Crohn’s disease. Data sources: We identified randomized controlled trials from…
Read MoreRelated Articles Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn’s Disease: A Bayesian Network Meta-Analysis: ERRATUM. Inflamm Bowel Dis. 2017 May 01;23(5):E25 Authors: PMID: 30052984 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30052984?dopt=Abstract
Read MorePhysicians’ Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn’s Disease. Dig Dis Sci. 2018 Jun 29;: Authors: Ma C, Ascoytia C, McCarrier KP, Martin M, Feagan BG, Jairath V Abstract BACKGROUND: Aminosalicylates are the most commonly prescribed therapy in Crohn’s disease (CD), despite uncertainty in the evidence to support their efficacy. AIMS: To examine physicians’ perspectives on aminosalicylate use for CD and explore the discordance between clinical practice and the evidence base. METHODS: A qualitative interview study was performed amongst physicians with at least 4 years…
Read More